Alivus Life Sciences Limited has announced its financial results for the first quarter ended June 30, 2026, reporting its highest-ever Profit After Tax (PAT). PAT grew by 31.8% YoY to Rs. 1,601 Mn, with PAT margins reaching 25.0%. Revenue from operations saw a 6.4% YoY growth, driven by the non-GPL business. The company also generated a strong free cash flow of Rs. 901 Mn.
Alivus Life Sciences Q1 FY27 Performance
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) today announced its financial results for the first quarter ended June 30, 2026, highlighting a record performance with the highest-ever Profit After Tax (PAT). The company reported a PAT of Rs. 1,601 Mn, marking a substantial 31.8% year-on-year growth. PAT margins stood strong at 25.0%, an increase of 480 basis points YoY.
Revenue and EBITDA Growth
Revenue from operations for Q1 FY27 reached Rs. 6,404 Mn, reflecting a 6.4% YoY growth. This performance was primarily driven by a robust expansion in the non-GPL business, which saw a significant 26.5% YoY increase. EBITDA for the quarter was reported at Rs. 2,341 Mn, a 29.1% YoY growth, with margins at an accelerated 36.6%. This was attributed to a favourable product mix, successful new launches, and operational leverage benefits.
Cash Flow and Balance Sheet Strength
The company demonstrated strong financial discipline by generating a free cash flow of Rs. 901 Mn during Q1 FY27. As of June 30, 2026, Alivus Life Sciences maintained a healthy cash position with Cash and Cash Equivalents (including short-term investments) amounting to Rs. 8,802 Mn. The company also reported being a net debt-free entity, highlighting its robust balance sheet and financial flexibility for future investments.
Strategic Outlook
Dr. Yasir Rawjee, MD & CEO, expressed confidence in the company’s resilience and momentum, particularly in the non-GPL business. Alivus Life Sciences anticipates revenue growth of 10% – 12% in FY27 and aims to sustain EBITDA margins in the 30%-32% range. Ongoing investments in capacity expansion and pipeline development are seen as crucial for future growth. The GPL business is expected to be stable in FY27, with a typical skew towards the second half of the fiscal year.
Additional Highlights
The company’s DMF/CEP filings have reached a cumulative total of 617 as of June 30, 2026. The HP API portfolio includes 29 APIs in the active grid, with 13 products validated and seven in advanced development stages. Capex updates include ongoing construction for Phase 1 (350 KL) and Phase 2 (115 KL) capacity at Solapur, expected to be completed in Q3 and Q4 FY27, respectively. A new state-of-the-art R&D facility is also under construction in Taloja, focusing on advanced research areas.
Source: BSE
